Why the study?
Does dalteparin (low-molecular-weight heparin) reduce deep venous thrombosis in patients in the acute phase of an ischemic stroke?
Does dalteparin (low-molecular-weight heparin) reduce deep venous thrombosis in patients in the acute phase of an ischemic stroke?
Answers are grounded in this paper and cite their sources.
Low-molecular-weight heparin significantly reduces the frequency of DVT in acute ischemic stroke patients, though the study was underpowered to assess safety.
In a group of 60 patients in the acute phase of an ischemic stroke the assumption that low-molecular-weight heparin Kabi 2165 in the dose of 2 X 2,500 anti-Xa units s.c. could prevent thromboembolic complications was tested using a double-blind, placebo-controlled, randomized trial design. Thirty patients were allocated to each group. Both treatment groups were comparable with regard to neurological status and general condition. In the Kabi 2165 group there were 6 cases of deep venous thrombosis (DVT) compared to 15 in the placebo group (p = 0.05). In the placebo group there were 4 deaths during the trial versus 9 in the Kabi-2165-treated group (NS). Cerebral bleeding complicated 2 cases in the placebo group versus 4 in the Kabi 2165 group (NS). These results indicate that in ischemic stroke patients Kabi 2165 2 X 2,500 anti-Xa units s.c./24 h reduces the frequency of DVT. Because of the small number of patients it is impossible to evaluate the safety.
No takes yet. Share an insight, caveat, or question.
Prins et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: